Investors may be looking to Exelixis Inc. for comfort during the biotech's Monday evening conference call, particularly after a series of analyses from a Phase II trial of cabozantinib (XL184) presented over the weekend at the American Society of Clinical Oncology's (ASCO) 2011 annual meeting sent shares tumbling 20.2 percent.